Pharmacosmos A/S

36 clinical trials · Sponsor

Record	Firm	Date
Effect of Trilaciclib in the Prevention of Myelosupression in Subjects With Limited-stage Small Cell Lung Cancer (NCT07473128)	Pharmacosmos A/S	2026-06-30
Multi-center Trial of Ferric Derisomaltose Versus no Intravenous Iron in Iron-deficient Subjects With Symptomatic Chronic Heart Failure (NCT06929806)	Pharmacosmos A/S	2025-05-01
A Randomized, Comparative, Double-blind Trial of Pentaisomaltose and Dimethyl Sulphoxide for Cryoprotection of Hematopoietic Stem Cells in Subjects With Multiple Myeloma or Malignant Lymphoma With a Need for Autologous Transplantation (NCT05545202)	Pharmacosmos A/S	2024-04-30
A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia or Low-risk Myelodysplastic Syndromes (NCT05693909)	Pharmacosmos A/S	2023-09-04
Multi-center Trial of Ferric Derisomaltose in Children 0 to <18 Years of Age With Iron Deficiency Anemia (NCT05179226)	Pharmacosmos A/S	2022-11-28
A Trial Comparing the Incidence of Hypophosphatemia in Relation to Treatment With Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease (NCT03466983)	Pharmacosmos A/S	2018-05-23
Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose or Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia (NCT03237065)	Pharmacosmos A/S	2017-10-30
Incidence of Hypophosphatemia After Treatment With Iron Isomaltoside/Ferric Derisomaltose vs Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia (NCT03238911)	Pharmacosmos A/S	2017-10-24

Track Pharmacosmos A/S automatically

Every clearance here is in the API, with alerts when new ones post.